Vita-herb Nutriceuticals v. Lonza: NR Patent Case Transferred to South Carolina
Vita-herb Nutriceuticals filed a patent infringement action against Lonza and its affiliates in Oregon’s District Court, asserting two patents covering nicotinamide riboside supplement formulations against Lonza’s CFS product line. After 468 days, Judge McShane ordered the case transferred to the District Court of South Carolina under 28 U.S.C. § 1404 — a venue convenience transfer with no merits ruling.
NR Supplement Patent Dispute Moves Venue After 468 Days in Oregon
On 6 December 2023, Vita-herb Nutriceuticals filed an infringement action in the Oregon District Court against Lonza, Lonza Bend, Inc., and Lonza Ltd, asserting US8895060B2 and US8846082B2 — two patents covering nicotinamide riboside (NR) dietary supplement compositions. The accused products were Lonza’s CFS 1000, CFS 1200, and CFS 1500 formulations. The case was assigned to Judge Michael J. McShane.
On 18 March 2025, Judge McShane ordered the action transferred to the Greenwood Division of the District Court of South Carolina, invoking 28 U.S.C. § 1404(a), which permits transfer to a more convenient forum for parties and witnesses. The transfer closed the Oregon docket with no ruling on infringement, validity, or claim construction. The litigation continues in South Carolina under a fresh docket.
The 468-day duration before transfer suggests contested venue briefing rather than an early stipulated transfer. The choice of Lonza’s South Carolina presence — Lonza Bend, Inc. aside — as the receiving forum is consistent with § 1404 analysis favouring the defendant’s principal place of business or relevant operations. The substantive merits, including claim scope of both NR patents, remain entirely unresolved and will now be litigated before the South Carolina court.
Filing to Case Transferred in 468 days
468 days in Oregon before transfer — typical § 1404 venue motions resolve within 6–12 months
Case transferred under § 1404: what the venue change means for both parties
28 U.S.C. § 1404 transfer: convenience, not dismissal
A § 1404(a) transfer relocates a civil action to another district where it could originally have been brought, when that forum is more convenient for parties and witnesses or serves the interests of justice. Critically, transfer preserves all claims — no merits ruling is made and neither party gains or loses on substance. The case restarts procedurally in South Carolina with the Oregon record intact.
No merits adjudicationVita-herb must now litigate in South Carolina
Transfer to South Carolina represents a strategic setback for Vita-herb, which selected Oregon as its filing venue. The plaintiff now faces increased logistical burden and must engage South Carolina counsel or rely on pro hac vice admission. However, all asserted patent claims survive intact — both US8895060B2 and US8846082B2 remain in suit and Vita-herb retains full ability to pursue infringement relief in the new forum.
Claims survive; venue shiftsLonza secures home-court advantage in South Carolina
The transfer to South Carolina’s Greenwood Division — proximate to Lonza’s U.S. operations — is a meaningful procedural win for the Lonza defendants. Litigating closer to relevant witnesses, documents, and facilities typically improves defense efficiency. Lonza Bend, Inc. and Lonza Ltd remain named defendants. The substantive invalidity and non-infringement defenses will now be developed before the South Carolina District Court.
Procedural win for LonzaNR supplement IP dispute unresolved — sector uncertainty continues
The transfer leaves the validity and infringement scope of two NR supplement patents fully open. Competitors and licensees in the nicotinamide riboside space cannot draw any conclusions from the Oregon proceeding. The case now enters South Carolina courts, where the ultimate ruling on claim scope will carry commercial weight for the broader NR ingredient supply chain and dietary supplement market.
NR patent validity still openFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Vita-herb Nutriceuticals | Individual | Nutraceutical IP licensor — holder of US8895060B2 and US8846082B2 (NR supplement formulations)Search in Eureka ↗ |
| Defendant | Lonza | Individual | Lonza Group and affiliates — global contract manufacturer and supplier of NR-based supplement ingredientsSearch in Eureka ↗ |
| Co-Defendant | Lonza Bend, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Lonza, Ltd | Company | Search in Eureka ↗ |
| Plaintiff counsel | Joseph Curtis Edmondson | Attorney | Counsel for Vita-herb NutriceuticalsSearch in Eureka ↗ |
| Plaintiff law firm | Law Office Of J. Curtis Edmondson | Law Firm | Representing Vita-herb NutriceuticalsSearch in Eureka ↗ |
| Presiding judge | Judge Michael J. McShane | Judge | Oregon District CourtSearch in Eureka ↗ |
Official order — verbatim text
The transfer order invokes 28 U.S.C. § 1404 on the basis of convenience and does not adjudicate any claim on the merits. The directive to transfer to the Greenwood Division — a specific divisional seat within South Carolina’s District Court — suggests Lonza’s operational connections to that geography were persuasive to Judge McShane. Neither party receives a substantive win or loss; the infringement and validity questions over both NR patents remain entirely open for the South Carolina court to decide.
US8895060B2 & US8846082B2 — Nicotinamide Riboside Supplement Formulations
US8895060B2 (application no. US11/581763) and US8846082B2 (application no. US11/386159) both protect formulations involving nicotinamide riboside (NR), a form of vitamin B3 that has attracted significant commercial interest as an NAD+ precursor in dietary supplements. The application numbers indicate these patents were filed in the mid-2000s, predating the mainstream NR supplement market and potentially establishing early priority positions in composition and formulation claims.
NR-based supplements represent a high-value and actively contested segment of the nutraceutical IP landscape, with multiple patent holders asserting rights over compositions, dosage forms, and methods of use. Vita-herb’s assertion of both patents against Lonza’s entire CFS product range suggests broad claim coverage is alleged. For ingredient suppliers, contract manufacturers, and finished-goods brands operating in the NR category, the outcome of this case — now proceeding in South Carolina — is commercially significant.
Should your NR supplement product be cleared against US8895060B2 and US8846082B2?
Any company formulating, supplying, or distributing nicotinamide riboside-based dietary supplement products — including capsule, powder, or beverage formats — should assess freedom-to-operate against both US8895060B2 and US8846082B2 before commercialisation. The continued pendency of this litigation in South Carolina means these patents remain active enforcement assets, and the claim scope is yet to be construed by any court.
PatSnap Eureka’s FTO Search Agent can map your specific NR formulation parameters against the asserted claims of both patents, surface relevant prior art from the mid-2000s application window, and identify design-around pathways. With two patents in suit and three accused product concentrations already identified, a targeted FTO analysis can prioritise claim elements most likely to drive the South Carolina proceedings.
Run a freedom-to-operate analysis on US8895060B2 to assess your product’s exposure
Run FTO in Eureka →Similar NR Supplement & Nutraceutical Patent Infringement Cases
Cases involving nicotinamide riboside and functional ingredient patents in U.S. District Courts — including comparable § 1404 venue transfers and multi-patent NR assertions.
What this case signals for the NR supplement IP landscape
A contested § 1404 transfer after 468 days reveals how NR patent disputes are shaping up across multiple U.S. forums.
Venue selection in NR supplement cases carries real strategic weight
Vita-herb’s Oregon filing — and Lonza’s successful transfer motion — illustrates that in specialty ingredient patent disputes, where defendants are chosen and what contacts they maintain in a district can override plaintiff venue strategy. Companies holding NR or other functional ingredient patents should map defendant facilities before filing.
Two-patent assertion strategy raises the claim-construction stakes
Asserting both US8895060B2 and US8846082B2 simultaneously means claim construction in South Carolina will need to address at least two patent families. Overlap or tension between the two patents’ claim scope could influence both infringement and invalidity arguments — particularly if prior art overlaps with the asserted claims across both applications.
Nutriceuticals v Lonza — key questions answered
Vita-herb Nutriceuticals filed a patent infringement action against Lonza and affiliates in Oregon’s District Court on 6 December 2023, asserting US8895060B2 and US8846082B2 against the CFS 1000, 1200, and 1500 product line. After 468 days, Judge McShane transferred the case to the Greenwood Division of South Carolina’s District Court under 28 U.S.C. § 1404. No merits ruling was issued in Oregon.
A transfer under 28 U.S.C. § 1404(a) is purely procedural — it relocates the case to a more convenient forum without adjudicating infringement or validity. Both US8895060B2 and US8846082B2 remain fully asserted against Lonza’s CFS products. The South Carolina District Court will conduct all substantive proceedings including claim construction, summary judgment, and any trial.
The accused products identified in the case are Lonza’s CFS 1000, CFS 1200, and CFS 1500. These appear to be nicotinamide riboside-based supplement formulations. The asserted patents cover NR supplement compositions filed under application numbers US11/581763 and US11/386159.
The transfer was ordered pursuant to 28 U.S.C. § 1404, which allows a court to transfer a case to a district where it could originally have been brought if transfer serves the convenience of parties and witnesses or the interests of justice. The order designated the Greenwood Division specifically, consistent with Lonza’s South Carolina operational presence. The 468-day duration before transfer suggests the venue question was contested.
US8895060B2 and US8846082B2 are both patents asserted by Vita-herb Nutriceuticals covering nicotinamide riboside dietary supplement formulations. They were filed under application numbers US11/581763 and US11/386159 respectively, suggesting mid-2000s priority dates. NR is a vitamin B3 derivative commercially significant as an NAD+ precursor, making these patents relevant to the broader dietary supplement and functional ingredient industry.
PatSnap Eureka searches patents and litigation data to answer instantly.